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Angiotensin II is an octapeptide whose effects are mediated by two types of receptors. AT1 receptors are responsible for the vasoconstrictor,
positive inotropic and growth promoting properties, while AT2 receptors have been linked to vasodilator and anti-mitogenic properties. In this
study we investigated the effects of selective AT2 receptor stimulation on myocardial contractility and lusitropy. Effects of selective AT2 receptor
activation were evaluated in rabbit right papillary muscles (n=96) by adding increasing concentrations of H-9395, an AT2 receptor agonist, alone or
in presence of a selective AT1 receptor antagonist (ZD-7155), or alternatively, by adding increasing concentrations of angiotensin II in presence of
ZD-7155. In the latter conditions, selective AT2 receptor activation was also performed in presence of NG-nitro-L-Arginine, indomethacin, proadifen,
hydroxocobalamin, apamin plus charybdotoxin, Hoe-140 or PD-123,319, as well as, after endocardial endothelium removal. Selective AT2
stimulation induced a negative inotropic and lusitropic effect in the first three protocols. This effect was completely abolished after selective removal
of the endocardial endothelium and blunted in presence of Hoe-140, hydroxocobalamin, apamin plus charybdotoxin and PD-123,319, but maintained
in presence of NG-nitro-L-Arginine, indomethacin or proadifen. Selective AT2 receptor stimulation induces a negative inotropic and lusitropic effect,
which is modulated by endocardial endothelium and mediated by bradykinin B2 receptors through NO release and calcium dependent potassium
channels activation. Such findings may help to better understand the therapeutic effects of selective AT1 antagonists, which are increasingly used for
treating cardiovascular diseases.
© 2007 Published by Elsevier B.V.Keywords: Angiotensin II; AT2 receptor; Endocardial endothelium; Inotropism1. Introduction
Angiotensin II mediates its biological actions by binding to
distinct membrane-bound receptors and activating multiple
intracellular pathways. In 1989, different research teams
independently provided evidence for the existence of two major
subtypes of angiotensin II receptors (Whitebread et al., 1989;
Chiu et al., 1989). These twomajor subtypes have been identified,
cloned and named as AT1 and AT2 (de Gasparo et al., 2000).⁎ Corresponding author. Tel.: +351 22 551 36 44; fax: +351 22 551 36 46.
E-mail address: amoreira@med.up.pt (A.F. Leite-Moreira).
1 Both authors equally contributed to the work presented in this article.
0014-2999/$ - see front matter © 2007 Published by Elsevier B.V.
doi:10.1016/j.ejphar.2007.09.026Angiotensin AT1 receptors are responsible for mediating the
classic stimulatory actions of angiotensin II on blood pressure,
water and sodium intake, renal sodium retention, secretion of
vasopressin and aldosterone and cell growth and proliferation
(de Gasparo et al., 2000; Gallinat et al., 2000).
Although the exact physiological functions of angiotensin
AT2 receptors are not established, it is known that these receptors
may offset or oppose the angiotensin AT1 receptor mediated
actions of angiotensin II on cell growth, blood pressure and fluid
intake (Gallinat et al., 2000). However, the different expression
and actions of angiotensin AT2 receptors within cardiovascular
tissues under certain physiological/pathological conditions
suggest that there is a far from complete understanding of the
role of angiotensin AT1/AT2 receptors in cardiovascular
regulation (Horiuchi et al., 1999). Angiotensin AT2 receptor
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Scheider and Lorell (Schneider and Lorell, 2001).
In fetal tissues, angiotensin AT2 receptor is the predominant
subtype expressed. After birth, its expression in mesenchimal
tissues rapidly decreases. The common misconception that
angiotensin AT2 receptors do not exist in appreciable amounts
in adult animal vasculature is however slowly changing. They are
located in many different vessel types, albeit at lower, but
functional levels. For example, in rat aorta these receptors
constitute about 30–40% of angiotensin II receptors (Chang and
Lotti, 1991). In adult rat cardiomyocytes, angiotensin AT2
receptors are expressed at low levels, being expressed in 8–
13% of cardiomyocytes (Busche et al., 2000), but are significantly
increased in hypertrophy (36%) and heart failure (112%) when
compared with controls (Lopez et al., 1994; Ohkubo et al., 1997;
Bartunek et al., 1999). In rabbit hearts, this receptor subtype is
almost totally absent in nervous, conductive and atrial tissue but,
in the ventricle, approximately 20% of the angiotensin II receptors
are AT2 (Brink et al., 1995). Angiotensin AT2 receptors also gain
particular prominence in adult human heart. In both normal
noninfarcted or hypertrophied human hearts, there is a predom-
inance of angiotensin AT2 receptor binding sites in the
myocardium, constituting about 69±4% of angiotensin II binding
sites (Regitz-Zagrosek et al., 1995; Matsubara, 1998; de Gasparo
et al., 2000; Johren et al., 2004).
There is an increasing amount of literature demonstrating the
role of angiotensinAT2 receptors in the regulation of both acute and
chronic cardiovascular function. Chronically, angiotensin AT2 re-
ceptors have been implicated in the inhibition of myocardial hy-
pertrophy (Booz and Baker, 1996; Bartunek et al., 1999), fibroblast
proliferation (Tsutsumi et al., 1998) and vascular cell hyperplasia
(Nakajima et al., 1995). The overexpression of angiotensin AT2
receptors in cardiomyocytes attenuates perivascular fibrosis by a
kinin/nitric oxide dependent mechanism (Kurisu et al., 2003). In a
rat model of chronic heart failure, left ventricular remodeling and
cardiac function were improved by blockade of angiotensin AT1
receptors (Liu et al., 1997). This effect may be partially explained
by a higher activation of angiotensin AT2 receptors.
In the vasculature, it has been demonstrated that acute angio-
tensin AT2 receptor stimulation leads to relaxation of isolated
arteries, including rabbit renal arterioles (Arima et al., 1997;
Endo et al., 1997), rabbit cerebral arteries (Haberl, 1994) and rat
mesenteric arteries (Widdop et al., 2002, 2003). In the human
heart, angiotensin II exerts an acute vasodilating effect in the
coronary microcirculation through angiotensin AT2 receptor
stimulation (Batenburg et al., 2004a,b). However, the effects of
acute angiotensin AT2 stimulation in myocardial function,
namely in myocardial inotropy and lusitropy, are not yet
known. The main objectives of the present study are to describe
the myocardial effects caused by angiotensin AT2 stimulation
and their underlying mechanisms.
2. Materials and methods
The investigation conforms to the Guide for the Care and
Use of Laboratory Animals published by US National Institutes
of Health (NIH Publication No 85-23, revised 1996).2.1. Experimental preparation
The effects of angiotensin II were studied in isolated right
papillary muscles of New Zealand White rabbits (Oryctolagus
cuniculus; 2.7±0.12 kg). Rabbits were anaesthetized with
sodium pentobarbital (25 mg/kg, iv) and the heart was quickly
excised. The tissues were immersed in a modified Krebs–
Ringer solution, at 35°C, with cardioplegic 2,3-butanedione
monoxime (3%) and calf serum (5%; Bio-Whittaker, St. Louis,
Maryland, USA). The modified Krebs–Ringer solutions
contained (in mM): NaCl 98, KCl 4.7, MgSO4 2.4, KH2PO4
1.2, CaCl2 1.8, NaHCO3 20, CH3COONa 5, C3H3O3Na 15,
glucose 4.5 and atenolol 0.02. Atenolol was used to prevent β-
adrenergic mediated effects. The solutions were in equilibrium
with 95% O2 and 5% CO2, maintaining the pH between 7.38-
7.42. Rabbit papillary muscles (n=96; length: 3.2±1.1 mm;
weight: 2.2±1.3 mg; cross-sectional area: 0.6±0.3 mm2;
preload: 5.0±1.1 mN) were then carefully dissected. After-
wards, they were vertically mounted in a 10 ml plexi glass organ
bath. The lower muscular end was fixed in a phosphorbronze
clip and the upper tendinous end was attached to an
electromagnetic length-tension transducer (University of
Antwerp, Belgium). Preload was initially set between 3 and
4 mN according to muscle dimensions. The preparations were
stimulated at 0.6 Hz with a voltage of 10% above threshold
(typically 3–6 mV) by rectangular pulses of 5 ms duration
through two platinum electrodes arranged longitudinally
alongside the entire muscle. Twenty minutes later, bathing
solutions were replaced by corresponding Krebs–Ringer
solutions without 2,3-butanedione monoxime. During the next
2 h, muscles were stabilized. Bathing solutions were then
replaced by corresponding Krebs–Ringer solutions without calf
serum and Lmax was calculated. Protocols were initiated after
obtaining two similar isotonic and isometric control twitches
separated by a 10 min in interval.
2.2. Experimental protocols
In a first set of protocols, we studied the effects of selective
angiotensin AT2 receptor stimulation. H-9395 (Nicotinoyl-Tyr-
Lys(Z-Arg)-His-Pro-Ile-OH, supplied from Bachem AG), an
agonist of angiotensin AT2 receptors, was added to the
superfusing solution in increasing concentrations (10−9, 10−8,
10−7, 10−6, 10−5 M) in basal conditions (n=15) and in the
presence of a selective antagonist of angiotensin AT1 receptors
(ZD-7155; 10−7 M; n=9). We also tested the effects of the
addition to the superfusing solution of increasing concentrations
of angiotensin II (10−8, 10−7, 10−6, 10−5 M) in presence of a
selective angiotensin AT1 receptor antagonist (ZD7155, 10
−6 M;
n=12). ZD-7155 is an angiotensin AT1 receptor competitive
antagonist that is approximately ten times more potent than
losartan in suppressing the angiotensin II-induced pressor
response (Junggren et al., 1996).
In a second set of protocols, we studied the underlying
mechanisms to the inotropic effect observed after selective
angiotensin AT2 receptor stimulation. This was performed by
adding increasing concentrations of angiotensin II (10−8, 10−7,
Fig. 1. Effects of increasing concentrations of H-9395, H-9395 plus ZD-7155 and
angiotensin II plus ZD-7155 on active tension (AT; A) and peak rate of tension
rise (dT/dtmax; B) or tension decline (dT/dtmin; C). On the axis, [X] represents the
concentrations of angiotensin II or H-9395, according to the respective protocol.
Selective stimulation of AT2 receptors induced negative inotropic and lusitropic
effects maximal for the concentration of 10−5 M. ⁎Pb0.05 vs. basal; ⁎⁎Pb0.05
vs. 10−8 M; ⁎⁎⁎Pb0.05 vs. 10−7 M; #Pb0.05 vs. 10−6 M.
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dihydro-1-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-
1,6-naphthyridin-2(1H)-onehydrochloride; 10−6 M) in different
experimental conditions: after removal of the endocardial
endothelium (n=7) and in the presence of NG-nitro-L-Arginine
(3 10−5 M; n=9), indomethacin (10−5 M; n=7), proadifen
(10−6 M; n=9), Hoe-140 (D-Arg-L-Arg-L-Pro-L-Hyp-Gly-L-(2-
thienyl)Ala-L-Ser-D-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-
L-(2α,3β,7aβ)-octahydro-1H-indole-2-carbonyl-L-Arg;
10− 7 M; n=6), hydroxocobalamin (10− 4 M; n=7) and
charybdotoxin plus apamin (10−7 M; n=9). These later
substances are inhibitors of the synthesis of nitric oxide,
prostaglandins or endothelium-derived hyperpolarizing factor
(through the inhibition of cytochrome P-450 monooxygenase
enzymes), an antagonist of bradykinin B2 receptors, a nitric
oxide scavenger, an IKCa and BKCa channel inhibitor and a
SKCa channel inhibitor, respectively.
The concentrations of NG-nitro-L-arginine, indomethacin,
hydroxocobalamin, apamin, charybdotoxin and proadifen were
selected on the basis of several studies showing that their
physiological effects in myocardial tissue preparations or whole
heart preparations are exerted by concentrations in the
micromolar range (Mohan et al., 1995; Kato et al., 2001;
Batenburg et al., 2004a,b; Berges et al., 2005).
Finally, the effects of angiotensin II in presence of ZD-7155
were evaluated after selective inhibition of angiotensin AT2
receptors with PD-123,319 (S-(+)-1-[(4-(Dimethylamino)-3-
methylphenyl)methyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-
1H-imidazo[4,5-c]pyridine-6-carboxylic acid di(trifluoroace-
tate) salt hydrate; 10−6 M; n=5).
Selective removal of the endocardial endothelium was
performed according to the methodology described by Brutsaert
and collaborators (Brutsaert et al., 1988). Briefly, this consisted
in the immersion of the papillary muscles in a 0.5% solution of
Triton X-100 during 1 s, followed by an abundant washout. Of
note, that in each experimental protocol all papillary muscles
were obtained from different animals. All chemicals, except H-
9395, were purchased from Sigma Chemical Co, St Louis, Mo.
2.3. Data analysis
Isotonic and isometric twitches were recorded and analyzed
with dedicated software (University of Antwerp, Belgium).
Selected parameters include: active tension (mN mm−2);
maximum velocity of tension rise (dT/dtmax, mN mm
−2 s−1);
maximum velocity of tension decline (dT/dtmin, mNmm
−2 s−1);
peak isotonic shortening (%Lmax); maximum velocity of
shortening (dL/dtmax, Lmax s
−1); maximum velocity of length-
ening (dL/dtmin, Lmax s
−1), time to half relaxation (ms) and
resting tension (mN mm−2).
2.4. Statistical methods
Values are means±S.E.M. Statistical significance was deter-
mined using analysis of variances (ANOVA) and Student–
Newman–Keuls for pairwise multiple comparisons. Pb0.05
was accepted as significant.3. Results
Baseline performance of rabbit papillary muscles was si-
milar in all experimental protocols. Mean values of the papil-
lary muscles contractile parameters were: active tension 27.9±
2.5 mN/mm2; dT/dtmax 185±15 mN/mm
2 s; dT/dtmin−161±
13 mN/mm2 s; peak shortening 10±0.8% of Lmax; dL/dtmax
0.72±0.04 Lmax·s
−1; dL/dtmin−2.4±0.17 Lmax·s−1; time to
half relaxation 385±10 ms.
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agonist H-9395 induced a concentration-dependent negative
inotropic effect (Fig. 1). This effect was maximal for the
concentration of 10−5 M, decreasing 16.4±6.8% active tension,
20.3±6.0% dT/dtmax, 19.6±7.3% dT/dtmin, 16.0±5.6% peak
shortening and 32.3±12.2% dL/dtmax (Pb0.05). The addition
of the same agonist in the presence of a selective angiotensin
AT1 receptor antagonist (ZD-7155) increased the selectivity ofFig. 2. Addition of increasing concentrations of angiotensin II in the presence of
a selective antagonist of AT1 receptors (ZD-7155) before and after selective
removal of endocardial endothelium. The variables analyzed were active tension
(AT; A) and peak rate of tension rise (dT/dtmax; B) or tension decline (dT/dtmin;
C). ⁎Pb0.05 vs. basal; ⁎⁎Pb0.05 vs. 10−8 M; ⁎⁎⁎Pb0.05 vs. 10−7 M;
#Pb0.05 vs. 10−6 M; +Pb0.05 vs. without endocardial endothelium.
Fig. 3. Negative inotropic effect induced by the addition of increasing
concentrations of angiotensin II in the presence of ZD-7155 and of NG-nitro-
L-Arginine, indomethacin, proadifen or hydroxocobalamin. Selected parameters
were active tension (AT; A) and peak rate of tension rise (dT/dtmax; B) and
decline (dT/dtmin; C). ⁎Pb0.05 vs. basal; ⁎⁎Pb0.05 vs. 10
−8 M; ⁎⁎⁎Pb0.05 vs.
10−7 M; #Pb0.05 vs. 10−6 M.the stimulation and caused a slight amplification of the negative
inotropic effect (Fig. 1). Selective angiotensin AT2 stimulation
using increasing concentrations of angiotensin II in the presence
of ZD-7155 also induced a dose-dependent negative inotropic
effect, decreasing at the maximal concentration of angiotensin II
29.9±8.2% active tension, 26.6±7.0% dT/dtmax, 32.9±9.1%
dT/dtmin, 26.8±7.0% peak shortening and 22.4±5.8% dL/dtmax.
This effect was not significantly different from the one observed
with the addition of H-9395 in the presence of ZD-7155.
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underlying the negative inotropic effect previously observed, by
adding increasing concentrations of angiotensin II in presence
of ZD-7155 in several experimental conditions.
The addition of increasing concentrations of angiotensin II in
presence of ZD-7155 after the selective removal of endocardial
endothelium abolished the negative inotropic effect previously
observed (Fig. 2).Fig. 4. Effects of increasing concentrations of angiotensin II plus ZD-7155 on
active tension (AT; A) and peak rate of tension rise (dT/dtmax; B) or tension
decline (dT/dtmin; C) in the absence and in the presence of Hoe-140, an
antagonist of bradykinin B2 receptors, and apamin plus charybdotoxin. ⁎Pb0.05
vs. basal; ⁎⁎Pb0.05 vs. 10−8 M; ⁎⁎⁎Pb0.05 vs. 10−7 M; #Pb0.05 vs. 10−6 M.
Fig. 5. Effects of increasing concentrations of angiotensin II plus ZD-7155
on active tension (AT; A) and peak rate of tension rise (dT/dtmax; B) or
tension decline (dT/dtmin; C) in the absence and in the presence of PD-
123,319, an antagonist of AT2 receptors. ⁎Pb0.05 vs. basal; ⁎⁎Pb0.05 vs.
10− 8 M; ⁎⁎⁎Pb0.05 vs. 10− 7 M; #Pb0.05 vs. 10− 6 M.The effects of angiotensin II in presence of ZD-7155 and
inhibitors of the synthesis of nitric oxide, prostaglandins or
endothelium-derived hyperpolarizing factor is shown in Fig. 3.
The inhibitors used were, as previously stated, NG-nitro-L-
Arginine, indomethacin and proadifen, respectively. In all three
protocols, the negative inotropic effect was not significantly
altered (Fig. 3). However, when angiotensin II was added in the
presence of ZD-7155 and hydroxocobalamin (a nitric oxide
scavenger) there was a significant attenuation of the negative
inotropic effect. In fact, at the maximal concentration of
Fig. 6. Schematic diagram of the pathways involved in angiotensin AT2 receptor
activation. Ang II: angiotensin II; AT2 R: angiotensin AT2 receptor; B2 R:
bradykinin B2 receptor; NO: nitric oxide; eNOS: constitutive nitric oxide
synthase.
266 P. Castro-Chaves et al. / European Journal of Pharmacology 578 (2008) 261–269angiotensin II there was a decrease of only 11.1±6.1% in active
tension, 9.1±4,5% in dT/dtmax, 8.9±6.3% in dT/dtmin, 10.5±
4.5% in peak shortening and 13.3±3.2% in dL/dtmax (Fig. 3).
Fig. 4 compares the effects of the addition of angiotensin II
in presence of ZD-7155 with or without an antagonist of B2
bradykinin receptors, Hoe-140. As can be seen in the graph
presented, the negative inotropic effect of angiotensin II in
presence of ZD-7155 was significantly blunted at the higher
concentration tested, decreasing 6.7±2.2% active tension, 9.5±
2.4% dT/dtmax, 6.1±0.9% peak shortening and 6.7±1.1% dL/
dtmax, without affecting dT/dtmin. The negative inotropic effect
induced by angiotensin AT2 stimulation was similarly blunted in
the presence of charybdotoxin plus apamin, which block IKCa,
BKCa and SKCa (Fig. 4).
The negative inotropic effect of the highest concentration of
angiotensin II in presence of ZD-7155 was also blunted by the
concomitant inhibition of angiotensin AT2 receptors with PD-
123,319, as can be seen in Fig. 5.
In what concerns myocardial relaxation, selective stimula-
tion of angiotensin AT2 receptors decreased dT/dtmin inducing a
negative lusitropic effect, as seen in Fig. 1. However, it did not
significantly alter myocardial resting length or passive tension
and thus acute myocardial distensibility.
4. Discussion
In the present study, we demonstrated that the selective
stimulation of rabbit myocardial angiotensin AT2 receptors
caused a negative inotropic and lusitropic effect.
This effect was observed both with an angiotensin AT2
receptor agonist (H-9395) and after the addition of angiotensin
II in presence of ZD-7155. The antagonist used in these
protocols is a selective competitive angiotensin AT1 receptor
antagonist that is approximately ten times more potent than
losartan in suppressing the angiotensin II induced pressor
response (Junggren et al., 1996). The addition of H-9395 in the
presence of ZD-7155 allowed us to increase the selectivity of
the stimulation and, in fact, we observed a slight amplification
of the negative inotropic effect, as shown in Fig. 1. In the twoprotocols using H-9395, the same magnitude of the effect was
now observed for a concentration of the agonist ten times lower.
On the contrary, and as expected, the negative inotropic effect
secondary to angiotensin AT2 receptors selective stimulation
was blunted in the presence of PD-123,319, an angiotensin AT2
receptor antagonist.
In what concerns the diastolic properties, selective angio-
tensin AT2 receptor stimulation induced a decrease in the peak
rate of tension decline (dT/dtmin), as can be seen in Fig. 1C,
reflecting a slowing of myocardial relaxation and thus a
negative lusitropic effect. However, when myocardial stiffness
was analyzed, this parameter was not significantly altered. It is
known from previous reports that a number of neurohumoral
agents, like nitric oxide (Heymes et al., 1999; Shah et al., 1994),
endothelin-1 (Leite-Moreira et al., 2003) and angiotensin II
(Leite-Moreira et al., 2006), may acutely modulate myocardial
distensibility. In particular, the effect of angiotensin II is
mediated by angiotensin AT1 receptor and protein kinase C
activation (Leite-Moreira et al., 2006). The present work is
concordant to these previous results since selective angiotensin
AT2 receptor stimulation did not seem to influence myocardial
distensibility.
In order to evaluate the role of the endocardial endothelium,
we selectively stimulated angiotensin AT2 receptors before and
after selective removal of endocardial endothelium. As shown
in Fig. 2, the negative inotropic and lusitropic effect of
angiotensin AT2 receptor stimulation was completely abolished
after endocardial endothelium removal. Cardiac endothelial
cells, like all other endothelial cells, express and release a
variety of auto-and paracrine agents, which directly influence
cardiac metabolism, growth, contractile performance, and
rhythmicity (Brutsaert, 2003). The synthesis, secretion, and
activities of these endothelium-derived substances are closely
linked.
It is known that the endothelium may be implicated in the
mediation of some of angiotensin AT2 receptor actions (Martin et
al., 2006). In the vasculature, angiotensin AT2 receptor
stimulation induces an acute vasodilating effect. In the presence
of an angiotensin AT1 receptor antagonist, angiotensin II caused
a 30% increase in the diameter of preconstricted, microperfused
rabbit afferent and efferent arterioles in a PD-123,319-sensitive
manner (Arima et al., 1997; Endo et al., 1997). This acute
angiotensin AT2 receptor-mediated vasodilator response may be
endothelium-dependent or independent and appears to involve a
range of signaling pathways, including nitric oxide and
bradykinin production, activation of cytochrome P-450 epox-
ygenase pathways and modulation of K+ channel activity
(Widdop et al., 2003). Moreover, in the human heart, it has been
recently shown that angiotensin AT2 receptor stimulation in
coronary microarteries induces endothelium-dependent vasodi-
lation which is mediated by bradykinin B2 receptors and nitric
oxide (Batenburg et al., 2004a). Nitric oxide released either from
cardiac endothelial cells or generated within cardiac myocytes
can directly influence cardiac contractile function (Shah et al.,
2000). Both endothelium-derived nitric oxide and exogenous
nitric oxide donors induce an earlier onset of myocardial
relaxation and/or reduce diastolic tone (Grocott-Mason et al.,
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oxide and prostaglandin I2 share a number of important
properties and that their synthesis and release from endothelial
cells are often coupled (Carter and Pearson, 1992). The
endothelium is also an important mediator of chronic angioten-
sin AT2 receptor actions. For instance, in a study performed by
Wharton et al. (Wharton et al., 1998) the density of angiotensin
AT2 binding sites in endocardial, interstitial, and infarcted
regions in the ventricles of patients with end-stage ischemic
heart disease or dilated cardiomyopathy is significantly
increased compared with the noninfarcted myocardium. And
in a rat model of chronic heart failure, left ventricular remodeling
and cardiac function were improved by blockade of angiotensin
AT1 receptors. This effect was inhibited by treatment with an
angiotensin AT2 receptor antagonist and also, in part, by
treatment with a bradykinin B2 receptor antagonist (Liu et al.,
1997). In pigs, infarct size was reduced after regional myocardial
ischemia by blockade of the angiotensin AT1 receptor, and this
reduction was abolished by pretreatment with the angiotensin
AT2 receptor antagonist PD-123,319 and by blockade of
bradykinin B2 receptors (Jalowy et al., 1998). The aforemen-
tioned reduction of perivascular fibrosis by overexpressed
cardiac angiotensin AT2 receptors after pressure overload was
abolished after blockade of the bradykinin B2 receptors or nitric
oxide synthase. Thus, as in the vasculature, the myocardial
kinin/nitric oxide system appears to be involved in angiotensin
AT2 receptor-mediated cardiac effects.
In order to further characterize the endothelium-dependent
negative inotropic effect, we tested the effects of selective
angiotensin AT2 receptor stimulation in the presence of NG-
nitro-L-Arginine, indomethacin, proadifen and hydroxocobala-
min, inhibitors of the synthesis of nitric oxide, prostaglandins
and endothelium-derived hyperpolarizing factor and a nitric
oxide scavenger, respectively. We observed that in the presence
of these substances, the magnitude of the negative inotropic and
lusitropic effect was not significantly altered except with
hydroxocobalamin, as seen in Fig. 3.
It is interesting that in the present protocols the inhibition of
nitric oxide synthesis with NG-nitro-L-Arginine did not
attenuate the negative inotropic effect. However, in the presence
of a nitric oxide scavenger, hydroxocobalamin, the negative
inotropic effect observed after selective angiotensin AT2
receptor stimulation was blunted. It is known that nitric oxide
synthase inhibitors, even at high concentrations, do not block
nitric oxide release completely (Cohen et al., 1997). In vivo and
in vitro studies (Dadisson et al., 1996; Danser et al., 1998) have
shown that bradykinin also induces nitric oxide from stores of
nitric oxide-containing factors, such as S-nitroso-thiols. Such
sources become depleted only on repeated exposure to
bradykinin or after prolonged nitric oxide synthase inhibition
(Danser et al., 2000). A nitric oxide scavenger such as
hydroxocobalamin may induce a more complete blockade of
nitric oxide and thus may explain the inability of NG-nitro-L-
Arginine to block the negative inotropic effect observed in the
present work.
Although it may be too simplistic to try and define their
properties independently from one another since many of theseendothelium-derived agents modulate the actions of the other
factors (Brutsaert, 2003), prostaglandins and endothelium-
derived hyperpolarizing factor do not seem to be directly
involved in the negative inotropic and lusitropic effect. This is
in contrast to what happens with other vasodilating and negative
inotropic pathways, like endothelin ETB receptor stimulation. In
fact, in the same animal species, the endothelium dependent
ETB-mediated negative inotropic effect is mediated by nitric
oxide and prostaglandins (Leite-Moreira and Bras-Silva, 2004).
Finally, we tested the role of bradykinin B2 receptors. In the
presence of Hoe-140, an antagonist of bradykinin B2 receptors,
the negative inotropic and lusitropic effect of selective
angiotensin AT2 receptor stimulation was significantly blunted
(Fig. 4). In the vasculature overexpression of angiotensin AT2
receptors increases bradykinin production presumably by
activating kininogenase(s) (Tsutsumi et al., 1998) and the
inhibition of this enzyme might be another way to demonstrate
an interaction between these two systems. Although this is true,
our primary objective was to demonstrate that bradykinin B2
receptors are involved in the mechanisms underlying angioten-
sin AT2 receptor stimulation. There are several evidences in
other organs that this interaction exists. In a study published by
Bergaya et al., 2004, the authors examined the possible
contribution of angiotensin AT2 receptors to the kinin-
dependent response to flow. They evaluated changes in outer
diameter after increases in flow rate in perfused arteries from
wild-type animals (TK+/+) and in tissue kallikrein-deficient
mice (TK–/–) in which the presence of angiotensin AT2 receptor
expression was verified. Their results showed that if bradykinin
B2 receptors are blocked or if the vascular kinin–kallikrein
system is inactivated, the angiotensin AT2 receptor antagonist
PD123319 no longer decreases the response to flow. Similarly,
if angiotensin AT2 receptors are blocked or not expressed, the
bradykinin B2 receptor antagonist Hoe-140 no longer inhibits
flow-induced dilation. Our results are in accordance with these
observations, since the blockade of bradykinin B2 receptors
with Hoe-140 attenuated the negative inotropic effect of
angiotensin AT2 receptor stimulation, thus suggesting that this
effect depends on angiotensin AT2 receptors stimulation and
requires the presence of both functional bradykinin B2 receptors
and an active vascular kinin–kallikrein system. In the heart,
there are also evidences linking these two systems. As shown by
Kurisu et al., 2003, bradykinin released from cardiomyocytes
through angiotensin AT2 receptor signaling activates endothe-
lial bradykinin B2 receptors, leading to activation of constitutive
nitric oxide synthas. They showed that this activation was
followed by nitric oxide-dependent inhibition of fibrosis in
perivascular fibroblasts. Our results suggest that these pathways
are also involved in the modulation of the angiotensin AT2
receptor dependent negative inotropic effect. This stresses the
role of bradykinin B2 receptors in the mediation of angiotensin
AT2 receptor actions in acute myocardial contractile parameters.
Since it is known that prostaglandin I2 is a key mediator of
bradykinin B2 receptors effects (Ignarro et al., 1987), it is
interesting that in the present protocols the inhibition of nitric
oxide synthesis with indomethacin did not significantly alter
myocardial contractile parameters.
268 P. Castro-Chaves et al. / European Journal of Pharmacology 578 (2008) 261–269The endothelium-dependent relaxation induced by bradyki-
nin cannot fully be attributed to the release of nitric oxide. As
demonstrated by Batenburg et al. in human coronary arteries
there are other mechanisms of endothelial-dependent vasor-
elaxation induced by bradykinin B2 receptor stimulation, such
as the activation of a number of ion channels located in the
smooth muscle cells that may account for “endothelium-
dependent hyperpolarization” (Batenburg et al., 2004b). These
channels are activated by factors other than nitric oxide and
products of cytochrome P450 epoxygenase (Busse et al., 2002;
Batenburg et al., 2004b). In the present study this was
confirmed, since the angiotensin AT2 receptor dependent
negative inotropic effect was blunted in the presence of apamin
and charybdotoxin, an IKCa and BKCa channel inhibitor and a
SKCa channel inhibitor, respectively.
In conclusion, the renin angiotensin system has a central role
in cardiovascular homeostasis both in healthy and non-healthy
individuals. Indeed the pharmacological interventions modu-
lating this neuro-humoral system are valuable tools in the
treatment of hypertension, myocardial infarction, heart failure
or renal failure. There are several ways of intervention within
the renin angiotensin system, namely by inhibiting angiotensin
converting enzyme or through the antagonization of angiotensin
AT1 receptors. In both of these interventions angiotensin AT2
receptors seem to be responsible for at least some of the
beneficial effects observed. The present study demonstrates, for
the first time, that angiotensin AT2 receptor stimulation induces
a negative inotropic effect, thus clarifying the role of these
receptors in myocardial contractility (Fig. 6). This effect was
significantly blunted after the selective removal of endocardial
endothelium or bradykinin B2 receptor inhibition. This may add
to the previous knowledge about the cardiac effects of
angiotensin AT2 receptor stimulation. Elucidation of the
beneficial role of the angiotensin AT2 in the human heart may
contribute to the establishment of more sophisticated methods
of treatment for human heart diseases.
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